Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
PDEX vs MMSI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
PDEX vs MMSI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $184M | $3.72B |
| Revenue (TTM) | $75M | $1.54B |
| Net Income (TTM) | $12M | $139M |
| Gross Margin | 27.8% | 48.7% |
| Operating Margin | 14.5% | 12.2% |
| Forward P/E | 24.1x | 15.5x |
| Total Debt | $17M | $898M |
| Cash & Equiv. | $419K | $449M |
PDEX vs MMSI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Pro-Dex, Inc. (PDEX) | 100 | 291.5 | +191.5% |
| Merit Medical Syste… (MMSI) | 100 | 138.5 | +38.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PDEX vs MMSI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PDEX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.33
- Rev growth 23.7%, EPS growth 345.0%, 3Y rev CAGR 16.6%
- 14.2% 10Y total return vs MMSI's 214.6%
MMSI is the clearest fit if your priority is value.
- Lower P/E (15.5x vs 24.1x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.7% revenue growth vs MMSI's 11.7% | |
| Value | Lower P/E (15.5x vs 24.1x) | |
| Quality / Margins | 16.1% margin vs MMSI's 9.0% | |
| Stability / Safety | Beta 0.33 vs MMSI's 0.71, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +34.4% vs MMSI's -33.8% | |
| Efficiency (ROA) | 18.3% ROA vs MMSI's 5.2%, ROIC 17.0% vs 7.2% |
PDEX vs MMSI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PDEX vs MMSI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — PDEX and MMSI each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MMSI is the larger business by revenue, generating $1.5B annually — 20.7x PDEX's $75M. PDEX is the more profitable business, keeping 16.1% of every revenue dollar as net income compared to MMSI's 9.0%. On growth, PDEX holds the edge at +14.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $75M | $1.5B |
| EBITDAEarnings before interest/tax | $13M | $290M |
| Net IncomeAfter-tax profit | $12M | $139M |
| Free Cash FlowCash after capex | $7M | $274M |
| Gross MarginGross profit ÷ Revenue | +27.8% | +48.7% |
| Operating MarginEBIT ÷ Revenue | +14.5% | +12.2% |
| Net MarginNet income ÷ Revenue | +16.1% | +9.0% |
| FCF MarginFCF ÷ Revenue | +9.5% | +17.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.6% | +7.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.4% | +38.8% |
Valuation Metrics
MMSI leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
At 21.5x trailing earnings, PDEX trades at a 27% valuation discount to MMSI's 29.3x P/E. On an enterprise value basis, MMSI's 13.1x EV/EBITDA is more attractive than PDEX's 16.8x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $184M | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $200M | $4.2B |
| Trailing P/EPrice ÷ TTM EPS | 21.51x | 29.26x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.13x | 15.46x |
| PEG RatioP/E ÷ EPS growth rate | 1.76x | — |
| EV / EBITDAEnterprise value multiple | 16.79x | 13.06x |
| Price / SalesMarket cap ÷ Revenue | 2.76x | 2.45x |
| Price / BookPrice ÷ Book value/share | 5.27x | 2.38x |
| Price / FCFMarket cap ÷ FCF | — | 17.24x |
Profitability & Efficiency
PDEX leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
PDEX delivers a 29.1% return on equity — every $100 of shareholder capital generates $29 in annual profit, vs $9 for MMSI. PDEX carries lower financial leverage with a 0.45x debt-to-equity ratio, signaling a more conservative balance sheet compared to MMSI's 0.57x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +29.1% | +8.9% |
| ROA (TTM)Return on assets | +18.3% | +5.2% |
| ROICReturn on invested capital | +17.0% | +7.2% |
| ROCEReturn on capital employed | +24.8% | +7.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.45x | 0.57x |
| Net DebtTotal debt minus cash | $16M | $450M |
| Cash & Equiv.Liquid assets | $419,000 | $449M |
| Total DebtShort + long-term debt | $17M | $898M |
| Interest CoverageEBIT ÷ Interest expense | 32.18x | 10.74x |
Total Returns (Dividends Reinvested)
PDEX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PDEX five years ago would be worth $16,706 today (with dividends reinvested), compared to $9,644 for MMSI. Over the past 12 months, PDEX leads with a +34.4% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors PDEX at 54.0% vs MMSI's -9.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +52.2% | -27.9% |
| 1-Year ReturnPast 12 months | +34.4% | -33.8% |
| 3-Year ReturnCumulative with dividends | +265.5% | -26.5% |
| 5-Year ReturnCumulative with dividends | +67.1% | -3.6% |
| 10-Year ReturnCumulative with dividends | +1423.1% | +214.6% |
| CAGR (3Y)Annualised 3-year return | +54.0% | -9.8% |
Risk & Volatility
PDEX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PDEX is the less volatile stock with a 0.33 beta — it tends to amplify market swings less than MMSI's 0.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PDEX currently trades 97.0% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.33x | 0.71x |
| 52-Week HighHighest price in past year | $59.22 | $100.19 |
| 52-Week LowLowest price in past year | $23.47 | $59.74 |
| % of 52W HighCurrent price vs 52-week peak | +97.0% | +62.2% |
| RSI (14)Momentum oscillator 0–100 | 69.2 | 34.9 |
| Avg Volume (50D)Average daily shares traded | 26K | 769K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PDEX as "Buy" and MMSI as "Buy".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $95.00 |
| # AnalystsCovering analysts | 1 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.9% | 0.0% |
PDEX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). MMSI leads in 1 (Valuation Metrics). 1 tied.
PDEX vs MMSI: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is PDEX or MMSI a better buy right now?
For growth investors, Pro-Dex, Inc.
(PDEX) is the stronger pick with 23. 7% revenue growth year-over-year, versus 11. 7% for Merit Medical Systems, Inc. (MMSI). Pro-Dex, Inc. (PDEX) offers the better valuation at 21. 5x trailing P/E (24. 1x forward), making it the more compelling value choice. Analysts rate Pro-Dex, Inc. (PDEX) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PDEX or MMSI?
On trailing P/E, Pro-Dex, Inc.
(PDEX) is the cheapest at 21. 5x versus Merit Medical Systems, Inc. at 29. 3x. On forward P/E, Merit Medical Systems, Inc. is actually cheaper at 15. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — PDEX or MMSI?
Over the past 5 years, Pro-Dex, Inc.
(PDEX) delivered a total return of +67. 1%, compared to -3. 6% for Merit Medical Systems, Inc. (MMSI). Over 10 years, the gap is even starker: PDEX returned +1423% versus MMSI's +214. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PDEX or MMSI?
By beta (market sensitivity over 5 years), Pro-Dex, Inc.
(PDEX) is the lower-risk stock at 0. 33β versus Merit Medical Systems, Inc. 's 0. 71β — meaning MMSI is approximately 119% more volatile than PDEX relative to the S&P 500. On balance sheet safety, Pro-Dex, Inc. (PDEX) carries a lower debt/equity ratio of 45% versus 57% for Merit Medical Systems, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — PDEX or MMSI?
By revenue growth (latest reported year), Pro-Dex, Inc.
(PDEX) is pulling ahead at 23. 7% versus 11. 7% for Merit Medical Systems, Inc. (MMSI). On earnings-per-share growth, the picture is similar: Pro-Dex, Inc. grew EPS 345. 0% year-over-year, compared to 4. 9% for Merit Medical Systems, Inc.. Over a 3-year CAGR, PDEX leads at 16. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PDEX or MMSI?
Pro-Dex, Inc.
(PDEX) is the more profitable company, earning 13. 5% net margin versus 8. 5% for Merit Medical Systems, Inc. — meaning it keeps 13. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PDEX leads at 16. 1% versus 12. 2% for MMSI. At the gross margin level — before operating expenses — MMSI leads at 48. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PDEX or MMSI more undervalued right now?
On forward earnings alone, Merit Medical Systems, Inc.
(MMSI) trades at 15. 5x forward P/E versus 24. 1x for Pro-Dex, Inc. — 8. 7x cheaper on a one-year earnings basis.
08Which pays a better dividend — PDEX or MMSI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is PDEX or MMSI better for a retirement portfolio?
For long-horizon retirement investors, Pro-Dex, Inc.
(PDEX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 33), +1423% 10Y return). Both have compounded well over 10 years (PDEX: +1423%, MMSI: +214. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PDEX and MMSI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PDEX is a small-cap high-growth stock; MMSI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.